OSRH OSRH
Company Profile ↓Company Overview
OSRH (OSRH) is a publicly traded company listed on with a market capitalization of $11.70M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.06.
Recent Developments
- Dec 2025 Revenue of $2.91M (-17.7% YoY); net profit $-18.01M.
- Trailing 12 Months Year-on-year growth — revenue -17.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -17.69% |
Stock Price Performance
| 1 Year: | -32.49% |
| 6 Months: | -22.83% |
| 3 Months: | -14.63% |
| 1 Month: | +40.83% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)53.86 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 56.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 823.00K | 761.27K | 1.14M | 627.75K | 381.27K | 484.06K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | 592.59K | 1.10M | 366.01K | 251.56K | 323.78K |
| Gross Profit | - | - | - | - | - | - | 239.80K | 232.32K | 179.09K | 168.69K | 32.78K | 261.73K | 129.70K | 160.28K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 3.09M | 5.26M | 4.07M | 6.52M | 3.83M |
| Operating Income | - | - | - | - | - | - | -3.30M | -3.21M | -3.57M | -2.92M | -5.23M | -3.80M | -6.39M | -3.67M |
| EBITDA | - | - | - | - | - | - | - | - | - | -9.10M | -2.84M | -2.06M | -5.08M | -1.46M |
| Interest Expense | - | - | - | - | - | - | - | - | - | 16.40K | 36.93K | 43.87K | 409.00K | 31.22K |
| Pretax Income | - | - | - | - | - | - | - | - | - | -11.39M | -5.23M | -4.49M | -7.78M | -3.92M |
| Tax Provision | - | - | - | - | - | - | - | - | - | 0 | 0 | -1.29M | -534.87K | -452.31K |
| Net Income | -126 | -988 | -20.02K | 110.31K | 301.46K | 78.18K | -60.43K | -97.30K | -230.96K | -11.39M | 331.41K | -2.13M | -4.82M | -2.93M |
| Diluted EPS | - | 0.00 | -0.01 | 0.02 | 0.03 | 0.01 | -0.01 | -0.02 | -0.06 | -1.04 | 0.02 | -0.10 | - | -0.09 |
| R&D Expense | - | - | - | - | - | - | 46.72K | - | - | 90.15K | - | - | - | 113.15K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 3.53M | 2.91M |
| Cost of Revenue | - | 0 | 2.53M | 2.72M | 2.31M |
| Gross Profit | - | 0 | 921.41K | 811.24K | 592.90K |
| Operating Expenses | - | 621.32K | 1.83M | 12.50M | 18.93M |
| Operating Income | -3.31K | -621.32K | -1.83M | -11.69M | -18.34M |
| EBITDA | - | 1.10M | 944.59K | -2.15M | -19.08M |
| Interest Expense | - | 14.22K | 0 | 51.34K | 506.20K |
| Pretax Income | - | 1.06M | 944.59K | -11.89M | -28.89M |
| Tax Provision | - | 0 | 540.81K | -1.56M | -1.83M |
| Net Income | -3.31K | 1.06M | 403.78K | -10.33M | -18.01M |
| Diluted EPS | - | 0.49 | 0.19 | -0.54 | -0.92 |
| R&D Expense | - | - | - | 161.16K | 318.45K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | 705.09K | 120.76M | 36.63M | 175.24M | 171.24M |
| Current Assets | - | - | 4.42M | 22.63K | 2.33M | 2.82M |
| Cash & Equivalents | - | 4.76K | 2.82M | 15.42K | 341.54K | 1.70M |
| Inventory | - | - | 1.08M | 1.80B | 922.11K | 196.43K |
| Receivables | - | - | 372.40K | 1.48B | 904.46K | 319.30K |
| Total Liabilities | - | 707.21K | 21.66M | 4.11M | 32.03M | 44.20M |
| Current Liabilities | - | 707.21K | 5.86M | 2.04M | 3.46M | 17.17M |
| Long Term Debt | - | - | 126.69K | 460.00M | 497.62K | - |
| Total Debt | - | - | 1.56M | 1.17B | 2.38M | 4.40M |
| Total Equity | 1.19K | -2.12K | 99.10M | 32.52M | 143.21M | 77.64M |
| Shares Outstanding | - | - | 19.28M | 19.28M | 19.28M | 26.60M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -461 | -516.31K | -818.77K | -1.85M | -4.33M |
| Investing Cash Flow | - | -1.71M | -33.83M | 503.61K | -2.64M |
| Financing Cash Flow | -57.44K | 4.72M | 34.54M | 1.18M | 8.37M |
| Capital Expenditure | - | -77.39K | -16.32K | - | -176.38K |
| Free Cash Flow | - | -593.70K | -818.77K | -1.85M | -4.50M |
| Net Change in Cash | - | 2.49M | -109.08K | -161.53K | 1.40M |
| Share Buybacks | - | - | 36.00M | 36.23M | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 23.0% | 20.4% |
| Operating Margin % | - | - | - | -331.2% | -631.0% |
| Net Margin % | - | - | - | -292.6% | -619.8% |
| ROE % | 156.0% | 1.1% | 1.2% | -7.2% | -23.2% |
| ROCE % | 156.0% | -0.5% | -5.3% | -6.8% | -11.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OSRH
Vaximm's Two Glioblastoma Studies Had No Dose-Limiting Toxicities - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNam50TTZjdGtvMG5VQzlWZVpITEY0YkpGeEJDQldJdXdhWC1QTnBRZV9MdEV3ZF9RZ3YxSVQwSnlRSV9yR251RFBNNWJuZWZaWFhpNFV3c2FvVGMtWHU0Z254UXM2TkVFX0M5dmVEbERweVhVSXlMUFEtNllKaW43T3dZdzNsOXBmVXhWZU…
VIAV Stock Jumps 17% On Q3 Beat – One Analyst Is ‘Even More Bullish Than Management’ - Stocktwits
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxNUkVRWGxMY1htcUNtNEw4NmpVYlpxZ2pRU2dZcjJUZjJqV0l5WkxKMFJmeVJHamlUTUI4YUxaNXBheXJhMFNaVUFBTUR3YlRkZXNPcld4cF9fVWg2UGtJamthM2g5eXk2R0tTLTJKOG01Nl9uWEJ3bDJrVEZHWVlUTzUxN1ZUakt4T3R2TE…
OSR Holdings Clarifies Nasdaq Treatment of Loyalty CVRs - theglobeandmail.com
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxQMWctZ1l0SS1XVEh4a2lWckMxQXVHVldjaTNySks3Z0VPQllUekN0NWkxSGM1WDRwb0s4cVdTTzJ3Qk1nNWtUc045S2xSUXJ3UjUzVFVaYlJ2U3ppeXhObHNBYmxyWGdoSE5aMjNSNXE1ak8yTTRCZ1pKYkFKblBva0dyVG44UTMtQllKcE…
OSR (OSRH) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
<a href="https://news.google.com/rss/articles/CBMiaEFVX3lxTE92YjBTX01JZW9vdVNLVmh1dzIzeVh3MDF6T2FabDhQTXprWUJPQjFSdFNSWm01T3pRTDhBNmhpOWxIYkNMOFlYUVJsTTNPRDg2UHlXTmVYTGRqQ3I5dGc5R1JfV2N5eEFx?oc=5" target="_blank">OSR (OSRH) FDA Approvals, P…
OSR Health Secures Nasdaq Communication: Loyalty CVR Program Will Not Trigger a Price Adjustment - newswire.com
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxNXzAyVkJtaTEzRU9hOHRiZGdyMkU0dXlhaFFEdjFKRmc1Y2x4NzlSTmd5bGVZOWhHdnFPNHo3bVl6dW9jSzlrZVZfSTREQThpWWs2eUozLTBsbFZSdE5ZWldyd3FVc2xuRjFnVGhmQmpxNFJzZ3ZIR2VUYjBuRUo1RGcwNVNJaHhIS1pqdH…
OSR Health, Inc. Revenue Breakdown – NASDAQ:OSRH - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE9nRnFmVGx2ZVZMNDJsekdfVnh6NHBZWFhXTFMydi1rT2pnTXEzVERNMElndEdiU3VQd1hHd0Z5UVJsZ3lCUy1tRTdnOEdRcUZtQW5zdjFIRF9nNmFPMFhiWVpjTTExdnpMZ2JrQUlPbHRQNkRuazVr?oc=5" target="_blank">OSR Hea…
OSRH — Frequently Asked Questions
What is the current share price of OSRH?
As of 2026-08-05 17:25 PDT, OSRH trades at $0.44 on NASDAQ/NYSE. Its 52-week range is $0.31 to $1.01.
What is the market capitalisation of OSRH?
OSRH has a market capitalisation of $11.70M on NASDAQ/NYSE.
What is the P/E ratio of OSRH?
OSRH trades at a trailing price-to-earnings (P/E) ratio of -0.48. Its price-to-book (P/B) ratio is 0.15.
What is the return on equity (ROE) of OSRH?
OSRH has a return on equity (ROE) of -23.20%. Its return on capital employed (ROCE) is -11.90%.
Is OSRH a good stock to buy?
This page provides a data-driven analysis of OSRH, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.